# Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

> **NCT05399498** · PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 9 (actual)

## Conditions studied

- Borderline Personality Disorder
- Major Depressive Disorder

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT05399498
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-12-23

## Collaborators

- Usona Institute

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05399498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05399498, "Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05399498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*